Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Antibody-Mediated Rejection in Adult Liver Transplant Recipients: A Case Series and Literature Review Publisher Pubmed



Baradaran H1, 2 ; Dashtikhavidaki S3 ; Taher M3, 4 ; Talebian M3 ; Nasiritoosi M3 ; Jafarian A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Students Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Division of Gastroenterology and Hepatology, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Tehran, Iran
  5. 5. Division of Hepatopancreatobiliary and Liver Transplantation, Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Clinical Pharmacology Published:2022


Abstract

Antibody-mediated rejection is a rare complication following liver transplantation, and there is a lack of a comprehensive treatment strategy to provide detailed information about the dose and duration of antibody-mediated rejection treatment. This study describes 8 adult liver transplantation recipients who developed antibody-mediated rejection between 2002 and 2021 in our center, as well as a review of the literature on the reported cases of antibody-mediated rejection in liver transplantation recipients. Our center's medical records were reviewed retrospectively to extract the necessary data on patients’ characteristics, management, and outcomes. Then, a comprehensive search using Embase, PubMed, Web of Science, Cochrane Library, and Google Scholar databases was conducted without time limitation until June 2021. Finally, a stepwise protocol was developed for managing acute, chronic, and recurrent antibody-mediated rejection in patients undergoing liver transplantation, based on our own experience, reported cases in the literature, and data from kidney transplantation. By review of the literature, 24 case studies containing 64 patients were identified, and their management strategies and outcomes were evaluated. Although various combinations of corticosteroids, plasma exchange, intravenous immunoglobulin, and biological agents are used in the treatment of acute antibody-mediated rejection in liver transplantation, treatment strategies should be classified according to the type, severity, and the timing of its onset. Given the importance of early treatment, rituximab and/or bortezomib should be started as soon as possible if no improvement in liver enzymes/bilirubin is observed during the initial treatment strategy using corticosteroids, plasma exchange, and intravenous immunoglobulin. © 2021, The American College of Clinical Pharmacology
Related Docs
1. Management of Drug-Induced Neutropenia, Thrombocytopenia, and Anaemia After Solid Organ Transplantation: A Comprehensive Review, Journal of Clinical Pharmacy and Therapeutics (2022)
Experts (# of related papers)
Simin Dashti-Khavidaki (1)